TRAILR1/TNFRSF10A Antibody (Mapatumumab) [DyLight 488]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28717G
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Functional
Label
DyLight 488 (Excitation = 493 nm, Emission = 518 nm)
Antibody Source
Recombinant Monoclonal Human IgG2 Clone # Mapatumumab
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
TNFRSF10A / TRAILR1 / CD261
Clonality
Monoclonal
Host
Human
Isotype
IgG2
Applications for TRAILR1/TNFRSF10A Antibody (Mapatumumab) [DyLight 488]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: TRAILR1/TNFRSF10A
Long Name
TRAIL Receptor 1
Alternate Names
CD261, DR4, TNFRSF10A, TRAIL R1
Gene Symbol
TNFRSF10A
Additional TRAILR1/TNFRSF10A Products
Product Documents for TRAILR1/TNFRSF10A Antibody (Mapatumumab) [DyLight 488]
Product Specific Notices for TRAILR1/TNFRSF10A Antibody (Mapatumumab) [DyLight 488]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...